ViroCure

What ViroCure does

ViroCure is a privately held biotechnology company headquartered in Seoul, South Korea, founded in 2016, that develops multiple virus-based platforms for cancer therapeutics and vaccine development. The company operates with a small team of 11–50 employees and is led by CEO Dong Guk Park. Its stated thesis is platform-based: viral vector or virus-engineering technologies are intended to be applied across both oncology and infectious-disease vaccine indications, which is a typical early-stage strategy to maximize optionality from a single underlying R&D capability.

The company's public information footprint is minimal. The corporate website (virocure.net) returns a placeholder landing page with no product pipeline, clinical assets, scientific publications, or commercial disclosures. No product names, indications, development stages, or platform architecture details are available in the input data. The only recorded funding event is a 2016 round attributed to investor ActnerLab with a $0 disclosed value, suggesting either an incubyator/grant-style arrangement or undisclosed financing terms. No partnerships, licensing deals, manufacturing arrangements, regulatory milestones, or named customers are documented.

The business model is therefore not yet commercially defined in publicly available terms. At this stage, ViroCure appears to be a pre-clinical / pre-revenue R&D-stage virology platform developer. Potential revenue mechanics typical for a company of this profile — research collaborations, licensing of platform IP, sponsored research, milestone-based co-development, and eventual out-licensing or product commercialization — are not confirmed in the data. The combination of limited disclosed capital, no visible pipeline, and a near-empty web presence constrains the analytical conclusions that can be drawn externally.

Name

ViroCure

Website

https://virocure.net

Company type

Private

Founded year

2016

Headcount range

11–50 employees

Short description

ViroCure is a privately held Seoul-based biotechnology company founded in 2016 that develops multiple virus-based platforms for cancer therapeutics and vaccine development, operating with a small team under CEO Dong Guk Park.

Ownership category

akta.pro rank

Product category

Oncolytic Virus Biotherapeutics

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

Keywords

• Oncolytic virus therapy
• Cancer immunotherapy
• Viral vaccine platforms
• Biopharmaceutical development
• Engineered virus therapeutics

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

ViroCure is developing multiple virus-based platforms intended for use in cancer therapeutics and vaccine development. The company's work centers on engineering viruses that can be deployed as oncolytic agents against tumors and as vectors for vaccines.

Differentiator

Problem solved

Functional benefit

Products and services

• Virus platforms for cancer therapeutics Engineered virus platforms designed for use as cancer therapeutics, intended for biopharma partners and clinical development.
• Virus platforms for vaccine development Virus-based platform technologies being developed for vaccine applications, leveraging engineered viruses as vaccine vectors.

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights2 records

Direct peers

• PsiOxus Therapeutics: Clinical-stage UK biotech developing the enadenotucirev and T-SIGn virus platforms for oncology and gene therapy delivery. Comparable as a multi-platform virus therapeutics developer with both cancer and vaccine-adjacent positioning.
• DNAtrix: Clinical-stage biotech developing oncolytic adenovirus therapies (DNX-2401) for glioblastoma and other cancers. Comparable as a viral platform oncology developer focused on multiple indications from a single backbone.
• SillaJen: Korean clinical-stage biotech developing oncolytic virus therapeutics (Pexa-Vec) for solid tumors. Directly comparable to ViroCure's virus-based cancer therapeutics work given shared Seoul base, viral platform, and oncology focus.
• Replimune: Clinical-stage US biotech developing a proprietary oncolytic immunotherapy platform (RP1, RP2, RP3) for cancer. Highly comparable in modality, virus-platform approach, and oncology therapeutic positioning.
• GeoVax Labs: Clinical-stage US biotech developing viral vector vaccine platforms (MVA-VLP, GEO-CM04S1) for infectious disease and cancer immunotherapy. Comparable multi-platform virus developer covering both vaccine and cancer indications.
• Targovax: Clinical-stage Norwegian biotech developing oncolytic virus and virus-based immunotherapy platforms (ofranergene obadenovec) for solid tumors. Directly comparable virus-platform approach to ViroCure's cancer therapeutics side.
• VBI Vaccines: Clinical-stage biotech developing enveloped virus-like particle (eVLP) and other viral platform technologies for vaccines against infectious disease and cancer. Comparable on the viral vaccine and cancer vaccine side of ViroCure's platform.
• CG Oncology: Clinical-stage biotech developing oncolytic virus therapy (cretorilimus/BC-819 + nadofaragene) for bladder and other cancers. Directly comparable as a viral platform oncology player with advanced clinical assets.

Broad incumbents

• ImmunityBio: Late-stage US biotech with a broad portfolio spanning viral vector vaccines, cytokine immunotherapies, and cancer vaccines (Anktiva, Adenovirus platforms). Comparable in deploying viral platforms across cancer therapeutics and vaccine development at greater scale.

Emerging players

• TheraVectys: French biotech developing lentiviral vector-based vaccines for infectious disease. Comparable as a virus-platform vaccine developer with a research-stage pipeline similar in maturity to a pre-clinical ViroCure.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/virocure

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ViroCure